Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependent
- 31 March 1994
- journal article
- Published by Elsevier in Transplant Immunology
- Vol. 2 (1) , 47-51
- https://doi.org/10.1016/0966-3274(94)90077-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Complement activation during OKT3 treatment: A possible explanation for respiratory side effectsKidney International, 1993
- Complement activation and pulmonary dysfunction in experimental Escherichia coli septicaemiaActa Anaesthesiologica Scandinavica, 1991
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activationEuropean Journal of Immunology, 1990
- OKT3 and pulmonary capillary permeability.BMJ, 1987
- PROPHYLACTIC USE OF OKT3 MONOCLONAL ANTIBODY IN CADAVER KIDNEY RECIPIENTS UTILIZATION OF OKT3 AS THE SOLE IMMUNOSUPPRESSIVE AGENTTransplantation, 1986
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985
- Role of Complement Activation in a Model of Adult Respiratory Distress SyndromeJournal of Clinical Investigation, 1980
- Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.Journal of Clinical Investigation, 1977
- Complement and Leukocyte-Mediated Pulmonary Dysfunction in HemodialysisNew England Journal of Medicine, 1977